LPP MOPP workstream continue to track the prescribing uptake of biosimilar etanercept, infliximab and rituximab. This is shared with stakeholders on a monthly basis including lost opportunity information. The savings on biosimilar uptake is reported quarterly as a part of the overall LPP MOPP savings report.
Future biosimilars in 2018 include the launches of three trastuzumab biosimilars between March and June. Biosimilar adalimumab will be launched late Oct 2018 with six companies granted marketing authorisations.